Business
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
BOSTON, February 25, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full‑year 2025 results and recent business performance.
About this update from Ironwood Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":251,"url":"https://media.zenfs.com/en/business-wire.com/49f2b2cad8ff96a55a74f4273a040ac6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/834CsxycQRiR7CuQzT3B_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/49f2b2cad8ff96a55a74f4273a040ac6","width":480,"height":251}},"lazy":false},{"type":"text","content":"– LINZESS® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year –","length":87,"tagName":"p","attribs":{}},{"type":"text","content":"– 2025 Ironwood revenue of $296 million, GAAP net income of $24 million and adjusted EBITDA of $138 million –","length":109,"tagName":"p","attribs":{}},{"type":"text","content":"– Continue to expect full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million –","length":178,"tagName":"p","attribs":{}},{"type":"text","content":"– Key elements of confirmatory Phase 3 clinical trial design of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) have been finalized with site initiations expected to begin in the second quarter of 2026 –","length":224,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, February 25, 2026--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full‑year 2025 results and recent business performance.","length":327,"tagName":"p"},{"type":"text","content":""In 2025, LINZESS delivered 11% EUTRx demand growth year-over-year, continuing to strengthen its position as the prescription market leader for the treatment of IBS-C and CIC, surpassing 5.7 million unique patients treated since launch. Additionally, throughout 2025 our disciplined approach to expense management allowed us to navigate LINZESS pricing headwinds, deliver $24 million in GAAP net income and $138 million in adjusted EBITDA and generate $127 million in cash flow from operations," said Tom McCourt, chief executive officer of Ironwood. "Importantly, we ended 2025 with $215 mill...